img

Global Anti-VEGT Drugs Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-VEGT Drugs Market Insights, Forecast to 2034

Anti-VEGF (Vascular Endothelial Growth Factor) drugs are a class of medications used to treat various eye conditions, particularly those affecting the retina and blood vessels at the back of the eye. VEGF is a protein that promotes the growth of new blood vessels. In certain eye diseases, excessive VEGF can contribute to abnormal blood vessel growth and leakage, causing vision problems or loss.
Anti-VEGF drugs work by inhibiting or blocking the activity of VEGF, thus helping to reduce the growth of abnormal blood vessels and fluid leakage within the eye. These drugs are administered directly into the eye using injections.
Global Anti-VEGT Drugs market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Anti-VEGT Drugs industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Anti-VEGT Drugs key manufacturers include Genentech (Roche), Regeneron Pharmaceuticals, Novartis, AstraZeneca, Bayer, Abbott, Santen, Pfizer and Sanofi, etc. Genentech (Roche), Regeneron Pharmaceuticals, Novartis are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Anti-VEGT Drugs were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Anti-VEGT Drugs market and estimated to attract more attentions from industry insiders and investors.
Anti-VEGT Drugs can be divided into Tyrosine Kinase Inhibitors, Monoclonal Antibodies and Others,, etc. Tyrosine Kinase Inhibitors is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Anti-VEGT Drugs is widely used in various fields, such as Oncology, Ophthalmology and Others,, etc. Oncology provides greatest supports to the Anti-VEGT Drugs industry development. In 2022, global % sales of Anti-VEGT Drugs went into Oncology filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Anti-VEGT Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Anti-VEGT Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Genentech (Roche)
Regeneron Pharmaceuticals
Novartis
AstraZeneca
Bayer
Abbott
Santen
Pfizer
Sanofi
Bristol-Myers Squibb
GlaxoSmithKline
Eli Lilly & Company
Chugai Pharma
Kanghong Pharmaceutical
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others

Segment by Application


Oncology
Ophthalmology
Others

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Anti-VEGT Drugs plant distribution, commercial date of Anti-VEGT Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Anti-VEGT Drugs introduction, etc. Anti-VEGT Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Anti-VEGT Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Anti-VEGT Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Anti-VEGT Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Tyrosine Kinase Inhibitors
1.2.3 Monoclonal Antibodies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Anti-VEGT Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Oncology
1.3.3 Ophthalmology
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-VEGT Drugs Sales Estimates and Forecasts 2018-2029
2.2 Global Anti-VEGT Drugs Revenue by Region
2.2.1 Global Anti-VEGT Drugs Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Anti-VEGT Drugs Revenue by Region (2018-2024)
2.2.3 Global Anti-VEGT Drugs Revenue by Region (2024-2029)
2.2.4 Global Anti-VEGT Drugs Revenue Market Share by Region (2018-2029)
2.3 Global Anti-VEGT Drugs Sales Estimates and Forecasts 2018-2029
2.4 Global Anti-VEGT Drugs Sales by Region
2.4.1 Global Anti-VEGT Drugs Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Anti-VEGT Drugs Sales by Region (2018-2024)
2.4.3 Global Anti-VEGT Drugs Sales by Region (2024-2029)
2.4.4 Global Anti-VEGT Drugs Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Anti-VEGT Drugs Sales by Manufacturers
3.1.1 Global Anti-VEGT Drugs Sales by Manufacturers (2018-2024)
3.1.2 Global Anti-VEGT Drugs Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Anti-VEGT Drugs in 2022
3.2 Global Anti-VEGT Drugs Revenue by Manufacturers
3.2.1 Global Anti-VEGT Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Anti-VEGT Drugs Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Anti-VEGT Drugs Revenue in 2022
3.3 Global Key Players of Anti-VEGT Drugs, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Anti-VEGT Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-VEGT Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-VEGT Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-VEGT Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Anti-VEGT Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Anti-VEGT Drugs Sales by Type
4.1.1 Global Anti-VEGT Drugs Historical Sales by Type (2018-2024)
4.1.2 Global Anti-VEGT Drugs Forecasted Sales by Type (2024-2029)
4.1.3 Global Anti-VEGT Drugs Sales Market Share by Type (2018-2029)
4.2 Global Anti-VEGT Drugs Revenue by Type
4.2.1 Global Anti-VEGT Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Anti-VEGT Drugs Forecasted Revenue by Type (2024-2029)
4.2.3 Global Anti-VEGT Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Anti-VEGT Drugs Price by Type
4.3.1 Global Anti-VEGT Drugs Price by Type (2018-2024)
4.3.2 Global Anti-VEGT Drugs Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Anti-VEGT Drugs Sales by Application
5.1.1 Global Anti-VEGT Drugs Historical Sales by Application (2018-2024)
5.1.2 Global Anti-VEGT Drugs Forecasted Sales by Application (2024-2029)
5.1.3 Global Anti-VEGT Drugs Sales Market Share by Application (2018-2029)
5.2 Global Anti-VEGT Drugs Revenue by Application
5.2.1 Global Anti-VEGT Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Anti-VEGT Drugs Forecasted Revenue by Application (2024-2029)
5.2.3 Global Anti-VEGT Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Anti-VEGT Drugs Price by Application
5.3.1 Global Anti-VEGT Drugs Price by Application (2018-2024)
5.3.2 Global Anti-VEGT Drugs Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Anti-VEGT Drugs Market Size by Type
6.1.1 US & Canada Anti-VEGT Drugs Sales by Type (2018-2029)
6.1.2 US & Canada Anti-VEGT Drugs Revenue by Type (2018-2029)
6.2 US & Canada Anti-VEGT Drugs Market Size by Application
6.2.1 US & Canada Anti-VEGT Drugs Sales by Application (2018-2029)
6.2.2 US & Canada Anti-VEGT Drugs Revenue by Application (2018-2029)
6.3 US & Canada Anti-VEGT Drugs Market Size by Country
6.3.1 US & Canada Anti-VEGT Drugs Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Anti-VEGT Drugs Sales by Country (2018-2029)
6.3.3 US & Canada Anti-VEGT Drugs Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Anti-VEGT Drugs Market Size by Type
7.1.1 Europe Anti-VEGT Drugs Sales by Type (2018-2029)
7.1.2 Europe Anti-VEGT Drugs Revenue by Type (2018-2029)
7.2 Europe Anti-VEGT Drugs Market Size by Application
7.2.1 Europe Anti-VEGT Drugs Sales by Application (2018-2029)
7.2.2 Europe Anti-VEGT Drugs Revenue by Application (2018-2029)
7.3 Europe Anti-VEGT Drugs Market Size by Country
7.3.1 Europe Anti-VEGT Drugs Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Anti-VEGT Drugs Sales by Country (2018-2029)
7.3.3 Europe Anti-VEGT Drugs Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Anti-VEGT Drugs Market Size
8.1.1 China Anti-VEGT Drugs Sales (2018-2029)
8.1.2 China Anti-VEGT Drugs Revenue (2018-2029)
8.2 China Anti-VEGT Drugs Market Size by Application
8.2.1 China Anti-VEGT Drugs Sales by Application (2018-2029)
8.2.2 China Anti-VEGT Drugs Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Anti-VEGT Drugs Market Size by Type
9.1.1 Asia Anti-VEGT Drugs Sales by Type (2018-2029)
9.1.2 Asia Anti-VEGT Drugs Revenue by Type (2018-2029)
9.2 Asia Anti-VEGT Drugs Market Size by Application
9.2.1 Asia Anti-VEGT Drugs Sales by Application (2018-2029)
9.2.2 Asia Anti-VEGT Drugs Revenue by Application (2018-2029)
9.3 Asia Anti-VEGT Drugs Sales by Region
9.3.1 Asia Anti-VEGT Drugs Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Anti-VEGT Drugs Revenue by Region (2018-2029)
9.3.3 Asia Anti-VEGT Drugs Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-VEGT Drugs Market Size by Type
10.1.1 Middle East, Africa and Latin America Anti-VEGT Drugs Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Anti-VEGT Drugs Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Anti-VEGT Drugs Market Size by Application
10.2.1 Middle East, Africa and Latin America Anti-VEGT Drugs Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Anti-VEGT Drugs Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Anti-VEGT Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America Anti-VEGT Drugs Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Anti-VEGT Drugs Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Anti-VEGT Drugs Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Genentech (Roche)
11.1.1 Genentech (Roche) Company Information
11.1.2 Genentech (Roche) Overview
11.1.3 Genentech (Roche) Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Genentech (Roche) Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Genentech (Roche) Recent Developments
11.2 Regeneron Pharmaceuticals
11.2.1 Regeneron Pharmaceuticals Company Information
11.2.2 Regeneron Pharmaceuticals Overview
11.2.3 Regeneron Pharmaceuticals Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Regeneron Pharmaceuticals Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Regeneron Pharmaceuticals Recent Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Overview
11.3.3 Novartis Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Novartis Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Novartis Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Overview
11.4.3 AstraZeneca Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 AstraZeneca Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 AstraZeneca Recent Developments
11.5 Bayer
11.5.1 Bayer Company Information
11.5.2 Bayer Overview
11.5.3 Bayer Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Bayer Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Bayer Recent Developments
11.6 Abbott
11.6.1 Abbott Company Information
11.6.2 Abbott Overview
11.6.3 Abbott Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Abbott Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Abbott Recent Developments
11.7 Santen
11.7.1 Santen Company Information
11.7.2 Santen Overview
11.7.3 Santen Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Santen Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Santen Recent Developments
11.8 Pfizer
11.8.1 Pfizer Company Information
11.8.2 Pfizer Overview
11.8.3 Pfizer Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Pfizer Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Pfizer Recent Developments
11.9 Sanofi
11.9.1 Sanofi Company Information
11.9.2 Sanofi Overview
11.9.3 Sanofi Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Sanofi Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Sanofi Recent Developments
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Information
11.10.2 Bristol-Myers Squibb Overview
11.10.3 Bristol-Myers Squibb Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Bristol-Myers Squibb Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Bristol-Myers Squibb Recent Developments
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Information
11.11.2 GlaxoSmithKline Overview
11.11.3 GlaxoSmithKline Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 GlaxoSmithKline Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 GlaxoSmithKline Recent Developments
11.12 Eli Lilly & Company
11.12.1 Eli Lilly & Company Company Information
11.12.2 Eli Lilly & Company Overview
11.12.3 Eli Lilly & Company Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Eli Lilly & Company Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Eli Lilly & Company Recent Developments
11.13 Chugai Pharma
11.13.1 Chugai Pharma Company Information
11.13.2 Chugai Pharma Overview
11.13.3 Chugai Pharma Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Chugai Pharma Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Chugai Pharma Recent Developments
11.14 Kanghong Pharmaceutical
11.14.1 Kanghong Pharmaceutical Company Information
11.14.2 Kanghong Pharmaceutical Overview
11.14.3 Kanghong Pharmaceutical Anti-VEGT Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Kanghong Pharmaceutical Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Kanghong Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Anti-VEGT Drugs Industry Chain Analysis
12.2 Anti-VEGT Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-VEGT Drugs Production Mode & Process
12.4 Anti-VEGT Drugs Sales and Marketing
12.4.1 Anti-VEGT Drugs Sales Channels
12.4.2 Anti-VEGT Drugs Distributors
12.5 Anti-VEGT Drugs Customers
13 Market Dynamics
13.1 Anti-VEGT Drugs Industry Trends
13.2 Anti-VEGT Drugs Market Drivers
13.3 Anti-VEGT Drugs Market Challenges
13.4 Anti-VEGT Drugs Market Restraints
14 Key Findings in The Global Anti-VEGT Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-VEGT Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Tyrosine Kinase Inhibitors
Table 3. Major Manufacturers of Monoclonal Antibodies
Table 4. Major Manufacturers of Others
Table 5. Global Anti-VEGT Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Anti-VEGT Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Anti-VEGT Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Anti-VEGT Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 9. Global Anti-VEGT Drugs Revenue Market Share by Region (2018-2024)
Table 10. Global Anti-VEGT Drugs Revenue Market Share by Region (2024-2029)
Table 11. Global Anti-VEGT Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Anti-VEGT Drugs Sales by Region (2018-2024) & (K Units)
Table 13. Global Anti-VEGT Drugs Sales by Region (2024-2029) & (K Units)
Table 14. Global Anti-VEGT Drugs Sales Market Share by Region (2018-2024)
Table 15. Global Anti-VEGT Drugs Sales Market Share by Region (2024-2029)
Table 16. Global Anti-VEGT Drugs Sales by Manufacturers (2018-2024) & (K Units)
Table 17. Global Anti-VEGT Drugs Sales Share by Manufacturers (2018-2024)
Table 18. Global Anti-VEGT Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Anti-VEGT Drugs Revenue Share by Manufacturers (2018-2024)
Table 20. Global Key Players of Anti-VEGT Drugs, Industry Ranking, 2021 VS 2022 VS 2024
Table 21. Anti-VEGT Drugs Price by Manufacturers 2018-2024 (US$/Unit)
Table 22. Global Anti-VEGT Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Anti-VEGT Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGT Drugs as of 2022)
Table 24. Global Key Manufacturers of Anti-VEGT Drugs, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Anti-VEGT Drugs, Product Offered and Application
Table 26. Global Key Manufacturers of Anti-VEGT Drugs, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Anti-VEGT Drugs Sales by Type (2018-2024) & (K Units)
Table 29. Global Anti-VEGT Drugs Sales by Type (2024-2029) & (K Units)
Table 30. Global Anti-VEGT Drugs Sales Share by Type (2018-2024)
Table 31. Global Anti-VEGT Drugs Sales Share by Type (2024-2029)
Table 32. Global Anti-VEGT Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Anti-VEGT Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 34. Global Anti-VEGT Drugs Revenue Share by Type (2018-2024)
Table 35. Global Anti-VEGT Drugs Revenue Share by Type (2024-2029)
Table 36. Anti-VEGT Drugs Price by Type (2018-2024) & (US$/Unit)
Table 37. Global Anti-VEGT Drugs Price Forecast by Type (2024-2029) & (US$/Unit)
Table 38. Global Anti-VEGT Drugs Sales by Application (2018-2024) & (K Units)
Table 39. Global Anti-VEGT Drugs Sales by Application (2024-2029) & (K Units)
Table 40. Global Anti-VEGT Drugs Sales Share by Application (2018-2024)
Table 41. Global Anti-VEGT Drugs Sales Share by Application (2024-2029)
Table 42. Global Anti-VEGT Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Anti-VEGT Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 44. Global Anti-VEGT Drugs Revenue Share by Application (2018-2024)
Table 45. Global Anti-VEGT Drugs Revenue Share by Application (2024-2029)
Table 46. Anti-VEGT Drugs Price by Application (2018-2024) & (US$/Unit)
Table 47. Global Anti-VEGT Drugs Price Forecast by Application (2024-2029) & (US$/Unit)
Table 48. US & Canada Anti-VEGT Drugs Sales by Type (2018-2024) & (K Units)
Table 49. US & Canada Anti-VEGT Drugs Sales by Type (2024-2029) & (K Units)
Table 50. US & Canada Anti-VEGT Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 51. US & Canada Anti-VEGT Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 52. US & Canada Anti-VEGT Drugs Sales by Application (2018-2024) & (K Units)
Table 53. US & Canada Anti-VEGT Drugs Sales by Application (2024-2029) & (K Units)
Table 54. US & Canada Anti-VEGT Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 55. US & Canada Anti-VEGT Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 56. US & Canada Anti-VEGT Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 57. US & Canada Anti-VEGT Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 58. US & Canada Anti-VEGT Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 59. US & Canada Anti-VEGT Drugs Sales by Country (2018-2024) & (K Units)
Table 60. US & Canada Anti-VEGT Drugs Sales by Country (2024-2029) & (K Units)
Table 61. Europe Anti-VEGT Drugs Sales by Type (2018-2024) & (K Units)
Table 62. Europe Anti-VEGT Drugs Sales by Type (2024-2029) & (K Units)
Table 63. Europe Anti-VEGT Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 64. Europe Anti-VEGT Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 65. Europe Anti-VEGT Drugs Sales by Application (2018-2024) & (K Units)
Table 66. Europe Anti-VEGT Drugs Sales by Application (2024-2029) & (K Units)
Table 67. Europe Anti-VEGT Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 68. Europe Anti-VEGT Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 69. Europe Anti-VEGT Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 70. Europe Anti-VEGT Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 71. Europe Anti-VEGT Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 72. Europe Anti-VEGT Drugs Sales by Country (2018-2024) & (K Units)
Table 73. Europe Anti-VEGT Drugs Sales by Country (2024-2029) & (K Units)
Table 74. China Anti-VEGT Drugs Sales by Type (2018-2024) & (K Units)
Table 75. China Anti-VEGT Drugs Sales by Type (2024-2029) & (K Units)
Table 76. China Anti-VEGT Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 77. China Anti-VEGT Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 78. China Anti-VEGT Drugs Sales by Application (2018-2024) & (K Units)
Table 79. China Anti-VEGT Drugs Sales by Application (2024-2029) & (K Units)
Table 80. China Anti-VEGT Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 81. China Anti-VEGT Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 82. Asia Anti-VEGT Drugs Sales by Type (2018-2024) & (K Units)
Table 83. Asia Anti-VEGT Drugs Sales by Type (2024-2029) & (K Units)
Table 84. Asia Anti-VEGT Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 85. Asia Anti-VEGT Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 86. Asia Anti-VEGT Drugs Sales by Application (2018-2024) & (K Units)
Table 87. Asia Anti-VEGT Drugs Sales by Application (2024-2029) & (K Units)
Table 88. Asia Anti-VEGT Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 89. Asia Anti-VEGT Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 90. Asia Anti-VEGT Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 91. Asia Anti-VEGT Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 92. Asia Anti-VEGT Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 93. Asia Anti-VEGT Drugs Sales by Region (2018-2024) & (K Units)
Table 94. Asia Anti-VEGT Drugs Sales by Region (2024-2029) & (K Units)
Table 95. Middle East, Africa and Latin America Anti-VEGT Drugs Sales by Type (2018-2024) & (K Units)
Table 96. Middle East, Africa and Latin America Anti-VEGT Drugs Sales by Type (2024-2029) & (K Units)
Table 97. Middle East, Africa and Latin America Anti-VEGT Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Anti-VEGT Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 99. Middle East, Africa and Latin America Anti-VEGT Drugs Sales by Application (2018-2024) & (K Units)
Table 100. Middle East, Africa and Latin America Anti-VEGT Drugs Sales by Application (2024-2029) & (K Units)
Table 101. Middle East, Africa and Latin America Anti-VEGT Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Anti-VEGT Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 103. Middle East, Africa and Latin America Anti-VEGT Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 104. Middle East, Africa and Latin America Anti-VEGT Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Anti-VEGT Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Anti-VEGT Drugs Sales by Country (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Anti-VEGT Drugs Sales by Country (2024-2029) & (K Units)
Table 108. Genentech (Roche) Company Information
Table 109. Genentech (Roche) Description and Major Businesses
Table 110. Genentech (Roche) Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. Genentech (Roche) Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Genentech (Roche) Recent Developments
Table 113. Regeneron Pharmaceuticals Company Information
Table 114. Regeneron Pharmaceuticals Description and Major Businesses
Table 115. Regeneron Pharmaceuticals Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. Regeneron Pharmaceuticals Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Regeneron Pharmaceuticals Recent Developments
Table 118. Novartis Company Information
Table 119. Novartis Description and Major Businesses
Table 120. Novartis Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Novartis Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Novartis Recent Developments
Table 123. AstraZeneca Company Information
Table 124. AstraZeneca Description and Major Businesses
Table 125. AstraZeneca Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. AstraZeneca Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. AstraZeneca Recent Developments
Table 128. Bayer Company Information
Table 129. Bayer Description and Major Businesses
Table 130. Bayer Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. Bayer Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Bayer Recent Developments
Table 133. Abbott Company Information
Table 134. Abbott Description and Major Businesses
Table 135. Abbott Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. Abbott Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Abbott Recent Developments
Table 138. Santen Company Information
Table 139. Santen Description and Major Businesses
Table 140. Santen Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 141. Santen Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Santen Recent Developments
Table 143. Pfizer Company Information
Table 144. Pfizer Description and Major Businesses
Table 145. Pfizer Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 146. Pfizer Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Pfizer Recent Developments
Table 148. Sanofi Company Information
Table 149. Sanofi Description and Major Businesses
Table 150. Sanofi Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 151. Sanofi Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. Sanofi Recent Developments
Table 153. Bristol-Myers Squibb Company Information
Table 154. Bristol-Myers Squibb Description and Major Businesses
Table 155. Bristol-Myers Squibb Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 156. Bristol-Myers Squibb Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Bristol-Myers Squibb Recent Developments
Table 158. GlaxoSmithKline Company Information
Table 159. GlaxoSmithKline Description and Major Businesses
Table 160. GlaxoSmithKline Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 161. GlaxoSmithKline Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 162. GlaxoSmithKline Recent Developments
Table 163. Eli Lilly & Company Company Information
Table 164. Eli Lilly & Company Description and Major Businesses
Table 165. Eli Lilly & Company Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 166. Eli Lilly & Company Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 167. Eli Lilly & Company Recent Developments
Table 168. Chugai Pharma Company Information
Table 169. Chugai Pharma Description and Major Businesses
Table 170. Chugai Pharma Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 171. Chugai Pharma Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 172. Chugai Pharma Recent Developments
Table 173. Kanghong Pharmaceutical Company Information
Table 174. Kanghong Pharmaceutical Description and Major Businesses
Table 175. Kanghong Pharmaceutical Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 176. Kanghong Pharmaceutical Anti-VEGT Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 177. Kanghong Pharmaceutical Recent Developments
Table 178. Key Raw Materials Lists
Table 179. Raw Materials Key Suppliers Lists
Table 180. Anti-VEGT Drugs Distributors List
Table 181. Anti-VEGT Drugs Customers List
Table 182. Anti-VEGT Drugs Market Trends
Table 183. Anti-VEGT Drugs Market Drivers
Table 184. Anti-VEGT Drugs Market Challenges
Table 185. Anti-VEGT Drugs Market Restraints
Table 186. Research Programs/Design for This Report
Table 187. Key Data Information from Secondary Sources
Table 188. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-VEGT Drugs Product Picture
Figure 2. Global Anti-VEGT Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Anti-VEGT Drugs Market Share by Type in 2022 & 2029
Figure 4. Tyrosine Kinase Inhibitors Product Picture
Figure 5. Monoclonal Antibodies Product Picture
Figure 6. Others Product Picture
Figure 7. Global Anti-VEGT Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Anti-VEGT Drugs Market Share by Application in 2022 & 2029
Figure 9. Oncology
Figure 10. Ophthalmology
Figure 11. Others
Figure 12. Anti-VEGT Drugs Report Years Considered
Figure 13. Global Anti-VEGT Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Anti-VEGT Drugs Revenue 2018-2029 (US$ Million)
Figure 15. Global Anti-VEGT Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 16. Global Anti-VEGT Drugs Revenue Market Share by Region (2018-2029)
Figure 17. Global Anti-VEGT Drugs Sales 2018-2029 ((K Units)
Figure 18. Global Anti-VEGT Drugs Sales Market Share by Region (2018-2029)
Figure 19. US & Canada Anti-VEGT Drugs Sales YoY (2018-2029) & (K Units)
Figure 20. US & Canada Anti-VEGT Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 21. Europe Anti-VEGT Drugs Sales YoY (2018-2029) & (K Units)
Figure 22. Europe Anti-VEGT Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 23. China Anti-VEGT Drugs Sales YoY (2018-2029) & (K Units)
Figure 24. China Anti-VEGT Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Asia (excluding China) Anti-VEGT Drugs Sales YoY (2018-2029) & (K Units)
Figure 26. Asia (excluding China) Anti-VEGT Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Anti-VEGT Drugs Sales YoY (2018-2029) & (K Units)
Figure 28. Middle East, Africa and Latin America Anti-VEGT Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 29. The Anti-VEGT Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Anti-VEGT Drugs in the World: Market Share by Anti-VEGT Drugs Revenue in 2022
Figure 31. Global Anti-VEGT Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Anti-VEGT Drugs Sales Market Share by Type (2018-2029)
Figure 33. Global Anti-VEGT Drugs Revenue Market Share by Type (2018-2029)
Figure 34. Global Anti-VEGT Drugs Sales Market Share by Application (2018-2029)
Figure 35. Global Anti-VEGT Drugs Revenue Market Share by Application (2018-2029)
Figure 36. US & Canada Anti-VEGT Drugs Sales Market Share by Type (2018-2029)
Figure 37. US & Canada Anti-VEGT Drugs Revenue Market Share by Type (2018-2029)
Figure 38. US & Canada Anti-VEGT Drugs Sales Market Share by Application (2018-2029)
Figure 39. US & Canada Anti-VEGT Drugs Revenue Market Share by Application (2018-2029)
Figure 40. US & Canada Anti-VEGT Drugs Revenue Share by Country (2018-2029)
Figure 41. US & Canada Anti-VEGT Drugs Sales Share by Country (2018-2029)
Figure 42. U.S. Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 43. Canada Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 44. Europe Anti-VEGT Drugs Sales Market Share by Type (2018-2029)
Figure 45. Europe Anti-VEGT Drugs Revenue Market Share by Type (2018-2029)
Figure 46. Europe Anti-VEGT Drugs Sales Market Share by Application (2018-2029)
Figure 47. Europe Anti-VEGT Drugs Revenue Market Share by Application (2018-2029)
Figure 48. Europe Anti-VEGT Drugs Revenue Share by Country (2018-2029)
Figure 49. Europe Anti-VEGT Drugs Sales Share by Country (2018-2029)
Figure 50. Germany Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 51. France Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 52. U.K. Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 53. Italy Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 54. Russia Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 55. China Anti-VEGT Drugs Sales Market Share by Type (2018-2029)
Figure 56. China Anti-VEGT Drugs Revenue Market Share by Type (2018-2029)
Figure 57. China Anti-VEGT Drugs Sales Market Share by Application (2018-2029)
Figure 58. China Anti-VEGT Drugs Revenue Market Share by Application (2018-2029)
Figure 59. Asia Anti-VEGT Drugs Sales Market Share by Type (2018-2029)
Figure 60. Asia Anti-VEGT Drugs Revenue Market Share by Type (2018-2029)
Figure 61. Asia Anti-VEGT Drugs Sales Market Share by Application (2018-2029)
Figure 62. Asia Anti-VEGT Drugs Revenue Market Share by Application (2018-2029)
Figure 63. Asia Anti-VEGT Drugs Revenue Share by Region (2018-2029)
Figure 64. Asia Anti-VEGT Drugs Sales Share by Region (2018-2029)
Figure 65. Japan Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 66. South Korea Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 67. China Taiwan Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 68. Southeast Asia Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 69. India Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Anti-VEGT Drugs Sales Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Anti-VEGT Drugs Revenue Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Anti-VEGT Drugs Sales Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Anti-VEGT Drugs Revenue Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Anti-VEGT Drugs Revenue Share by Country (2018-2029)
Figure 75. Middle East, Africa and Latin America Anti-VEGT Drugs Sales Share by Country (2018-2029)
Figure 76. Brazil Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 77. Mexico Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 78. Turkey Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 79. Israel Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 80. GCC Countries Anti-VEGT Drugs Revenue (2018-2029) & (US$ Million)
Figure 81. Anti-VEGT Drugs Value Chain
Figure 82. Anti-VEGT Drugs Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries